Evidence map›Paper›PMID 42464636›Full record

ArticleMolecular oncology2026

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER

Anneka L Johnson Thomas, Barbara Karakyriakou, Patricia C Muskus, Alyssa M Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A Birmingham, Malone K Friedman, Abigail E Goen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anneka L Johnson ThomasDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Barbara KarakyriakouDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Patricia C MuskusDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
Alyssa M RobertsDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Justin RendlemanLaboratory of Genome Architecture and Dynamics, The Rockefeller University, New York, NY, USA.
Alexa WarrenDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Hanxu LuDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Kimberly A BirminghamDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
Malone K FriedmanDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.
Abigail E GoenDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Huijuan YangDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Owen M WilkinsDepartment of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Fred W KollingDartmouth Cancer Center, Dartmouth Geisel School of Medicine, Hanover, NH, USA.
Eugene DemidenkoDepartment of Biostatistics, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Julie M JornsDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
Brock C ChristensenDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.
Todd W MillerDepartment of Molecular and Systems Biology, Dartmouth Geisel School of Medicine, Lebanon, NH, USA.ORCID https://orcid.org/0000-0001-8912-2909

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Zhao - Proj 2P20GM130454 · NIGMS · DARTMOUTH COLLEGE · PI MICHAEL L WHITFIELD · 2019 to 2026
$27.2M
A precision medicine basis for estrogen therapy for advanced breast cancerR01CA200994 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Todd W. Miller · 2017 to 2026
$3.7M
Therapeutically leveraging metabolic vulnerabilities in breast cancerR01CA262232 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Todd W. Miller · 2022 to 2026
$2.2M
Acquisition of the NextSeq2000 Sequencing platform to Increase Next Generation Sequencing Throughput While Reducing Costs at DartmouthS10OD030242 · OD · DARTMOUTH COLLEGE · PI KOLLING IV, FRED W · 2021 to 2021
$321k
NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA200994NCI NIH HHS R01 CA262232NIGMS NIH HHS P20 GM130454NIH HHS P20GM130454NIH HHS P30CA023108NIH HHS R01CA200994NIH HHS R01CA262232NIH HHS S10 OD030242NIH HHS S10OD030242
6 · The paper itself

Abstract

Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine-resistant estrogen receptor (ER)-positive breast cancer, but its mechanism of action and strategies to increase efficacy remain unclear. Estrogen therapy can induce ER transcriptional hyperactivation and DNA damage; we postulated that such damage could be exacerbated by epigenetic dysregulation via inhibition of histone deacetylases (HDACi). We evaluated the effects of 17b-estradiol and HDACi in three types of ER

Indexed as

breast cancerendocrine resistanceestrogen therapy

Identifiers

PMID42464636
PMCPMC13398958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.